TQB3811
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 03, 2021
A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Not yet recruiting ➔ Recruiting; Initiation date: Sep 2021 ➔ Nov 2021
Clinical • Enrollment open • Trial initiation date • Oncology • Solid Tumor
September 16, 2021
A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors
(clinicaltrials.gov)
- P1; N=30; Not yet recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Clinical • New P1 trial • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1